Fig. 1: Trends in oncotype DX recurrence score (ODX RS) testing over time.
From: The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment
A overall and stratified by B age group C nodal status, and D age and nodal status, among women with HR+/HER2–, early-stage breast cancer.
